2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
08/09/18Histogenics Corporation Announces Second Quarter 2018 Financial and Operating Results
‒ Top-line Superiority Data from NeoCart® Phase 3 Clinical Trial on Track for Third Quarter of 2018 ‒ ‒ Initiation of Phase 3 Clinical Trial in Japan Expected in Second Half of 2018 ‒ ‒ Expansion of Management Team in Preparation for Potential Commercialization of NeoCart in 2020 ‒ ‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT ‒ WALTHAM, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of resto... 
Printer Friendly Version
07/31/18Histogenics Corporation Appoints E. Lynne Kelley, M.D., FACS As Chief Medical Officer
Experienced Surgeon and Life Sciences Executive to Lead Medical Affairs, Clinical and Regulatory Operations in Preparation for Potential Commercial Launch of NeoCart® WALTHAM, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset pain relief and restored function, today announced the appointment of E. Lynne Kelley, M.D., FACS as its Chief Medical Officer. Dr. Kel... 
Printer Friendly Version
07/26/18Histogenics Corporation to Report Second Quarter 2018 Financial Results on August 9, 2018
WALTHAM, Mass., July 26, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its second quarter 2018 financial results on August 9, 2018, before the U.S. financial markets open.  The Company will host a conference call on Thursday, August 9, 2018 at 8:30 a.m. EDT.  To access the live call, please dial (877) 930-8064 (domestic) or (253) ... 
Printer Friendly Version
07/25/18Histogenics Corporation to Present at Canaccord Genuity’s 38th Annual Growth Conference
WALTHAM, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Adam Gridley, Chief Executive Officer of Histogenics, will be presenting a corporate overview at Canaccord Genuity’s 38th Annual Growth Conference on August 8, 2018 at 1:30 PM EDT at the InterContinental Boston Waterfront, Boston, MA.  To access a live audi... 
Printer Friendly Version
07/23/18Histogenics Chief Operating Officer, Stephen Kennedy Appointed to Advanced Regenerative Manufacturing Institute’s Technology Advisory Sub-Committee
WALTHAM, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Stephen Kennedy, Executive Vice President & Chief Operating Officer, has been appointed to the BioFabUSA Leadership Advisory Council and Technology Advisory Subcommittee (TASC) of the Advanced Regenerative Manufacturing Institute (ARMI). ARMI is a new p... 
Printer Friendly Version
05/31/18Histogenics Corporation to Host Investor Day on June 19, 2018
WALTHAM, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Histogenics will host its first Investor Day on Tuesday, June 19, 2018, in New York City. Members of Histogenics’ management team will provide a corporate overview and discuss the commercialization plan for NeoCart®, Histogenics’ lead investigational product, designed to reb... 
Printer Friendly Version
05/10/18Histogenics Corporation Announces First Quarter 2018 Financial and Operating Results
‒ Top-line Superiority Data from NeoCart® Phase 3 Clinical Trial and Potential Biologics License Application Submission on Track for Third Quarter of 2018 ‒ ‒ Initiation of Phase 3 Clinical Trial in Japan Expected in Second Half of 2018 ‒ ‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT ‒ WALTHAM, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rap... 
Printer Friendly Version
04/26/18Histogenics Corporation to Report First Quarter 2018 Financial Results on May 10, 2018
WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its first quarter 2018 financial results on May 10, 2018, before the U.S. financial markets open.  The Company will host a conference call on Thursday, May 10, 2018 at 8:30 a.m. EDT.  To access the live call, please dial (877) 930-8064 (domestic) or (253) 336-... 
Printer Friendly Version
04/18/18Histogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors
Experienced Life Sciences Executive to Serve as Member of Histogenics Board of Directors WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset pain relief and restored function, today announced the appointment of Susan Washer to its Board of Directors.  “Having known and worked with Sue for over 15 years, we are extremely pleased to welcome her to Hi... 
Printer Friendly Version
03/28/18Histogenics Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Company Management will be presenting at two upcoming healthcare investor conferences.  H.C. Wainwright Global Life Sciences Conference – Monte Carlo, Monaco (April 8-10, 2018) Jonathan Lieber, Histogenics’ CFO, will present a corporate overview on ... 
Printer Friendly Version
03/19/18Histogenics Corporation to Present at Needham & Company’s 17th Annual Healthcare Conference
WALTHAM, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Adam Gridley, Chief Executive Officer of Histogenics, will be presenting a corporate overview at Needham & Company’s 17th Annual Healthcare Conference on, March 28, 2018 at 11:00 AM EDT at the Westin Grand Central Hotel in New York, NY.  To access a li... 
Printer Friendly Version
03/15/18Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2017
NeoCart® Top-line Phase 3 Clinical Trial Data and Potential Biologics License Application Filing Remain on Track for Third Quarter of 2018 NeoCart Licensing Agreement with MEDINET Co. Ltd. Provides Important Source of Funding and Enables Development and Potential Commercialization in Japanese Market Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT WALTHAM, Mass., March 15, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the dev... 
Printer Friendly Version
03/02/18Histogenics to Showcase NeoCart® at American Academy of Orthopedic Surgeons and Orthopedic Research Society 2018 Annual Meetings
WALTHAM, Mass., March 02, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced today that it will be exhibiting at the American Academy of Orthopedic Surgeons (AAOS) and presenting at the Orthopedic Research Society (ORS) Annual Meetings, which are held consecutively in New Orleans, LA, from March 6, 2018 to March 13, 2018.   During the A... 
Printer Friendly Version
03/01/18Histogenics Corporation to Report 2017 Financial Results on March 15, 2018
WALTHAM, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report financial results for the quarter and year ended December 31, 2017, on March 15, 2018, before the market opens.  Histogenics’ management will host a conference call on Thursday, March 15, 2018 at 8:30 a.m. EDT.  A question-and-answer session will follow Histog... 
Printer Friendly Version
02/20/18Histogenics Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Company Management will be presenting at two upcoming healthcare investor conferences.  Canaccord Genuity 2018 Musculoskeletal Conference – New Orleans (March 6, 2018) Adam Gridley, Histogenics’ CEO, will present a corporate overview on Tuesday, Marc... 
Printer Friendly Version
01/25/18Histogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
WALTHAM, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the closing of its previously announced underwritten registered direct offering of 2,691,494 shares of its common stock, which includes 351,064 shares sold in connection with the exercise in full by the underwriter of its option to purchase additional shares. The total net proceeds of the offering are approximately $5.... 
Printer Friendly Version
01/22/18Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock
WALTHAM, Mass., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an underwritten registered direct offering of 2,340,430 shares of its common stock at a price of $2.35 per share. In connection with the offering, Histogenics granted the underwriter a 30-day option to purchase up to an additional 351,064 shares of common stock. All of the shares in the offering are bein... 
Printer Friendly Version
01/09/18Histogenics Corporation Announces Receipt of $10 Million Up-front Payment for Japanese Neocart Agreement
WALTHAM, Mass., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that it has received the $10 million up-front payment from MEDINET Co., Ltd. (MEDINET), under the previously announced agreement for the development and commercialization of NeoCart® for the Japanese market.  Per the terms of the agreement, the up-front payment was... 
Printer Friendly Version